Brokerages Set Hims & Hers Health, Inc. (NYSE:HIMS) Price Target at $20.71

Hims & Hers Health, Inc. (NYSE:HIMS) has received a consensus recommendation of “Hold” from the sixteen research firms that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have issued a buy rating on the company. The average 12-month price target among brokers that have covered the stock in the last year is $20.71.

A number of equities analysts have commented on HIMS shares. Needham & Company LLC began coverage on shares of Hims & Hers Health in a research report on Thursday, August 22nd. They issued a “buy” rating and a $24.00 price target on the stock. Canaccord Genuity Group lifted their target price on shares of Hims & Hers Health from $24.00 to $28.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Piper Sandler restated a “neutral” rating and set a $21.00 price target (up from $18.00) on shares of Hims & Hers Health in a research report on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft lifted their price objective on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research report on Wednesday, November 6th. Finally, Imperial Capital cut Hims & Hers Health from an “outperform” rating to an “in-line” rating in a report on Friday, August 9th.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, COO Melissa Baird sold 58,750 shares of the company’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $21.04, for a total transaction of $1,236,100.00. Following the sale, the chief operating officer now directly owns 630,166 shares of the company’s stock, valued at approximately $13,258,692.64. This represents a 8.53 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Oluyemi Okupe sold 142,886 shares of the firm’s stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $29.93, for a total transaction of $4,276,577.98. Following the completion of the sale, the chief financial officer now owns 112,186 shares of the company’s stock, valued at $3,357,726.98. This trade represents a 56.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,056,183 shares of company stock valued at $21,501,682. Company insiders own 17.71% of the company’s stock.

Institutional Trading of Hims & Hers Health

Several institutional investors and hedge funds have recently bought and sold shares of HIMS. Nisa Investment Advisors LLC lifted its holdings in Hims & Hers Health by 679.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after purchasing an additional 1,603 shares during the last quarter. Quest Partners LLC lifted its stake in shares of Hims & Hers Health by 5,944.1% during the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock worth $72,000 after buying an additional 3,507 shares during the last quarter. CWM LLC boosted its holdings in shares of Hims & Hers Health by 21.4% during the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after buying an additional 1,054 shares during the period. Van ECK Associates Corp bought a new stake in shares of Hims & Hers Health during the 2nd quarter worth about $111,000. Finally, Quarry LP grew its position in shares of Hims & Hers Health by 91.0% in the third quarter. Quarry LP now owns 6,113 shares of the company’s stock valued at $113,000 after purchasing an additional 2,913 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Stock Up 4.9 %

NYSE:HIMS opened at $25.33 on Thursday. The firm has a market capitalization of $5.53 billion, a PE ratio of 57.57 and a beta of 1.06. Hims & Hers Health has a 12-month low of $8.02 and a 12-month high of $30.44. The firm has a 50-day moving average price of $20.55 and a 200 day moving average price of $19.26.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.26. The company had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company’s revenue was up 77.1% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.04) EPS. On average, research analysts expect that Hims & Hers Health will post 0.29 EPS for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.